Aarti Pharmalabs Ltd (AARTIPHARM) Q4FY26 Management Mirror - Mar-2026 Qtr
Financial Outlook and Margins
Management targets 15% to 18% revenue and EBITDA growth over the next three to four years, following a Dec'25 Qtr downgrade that expected flat YoY EBITDA for the year ending Mar'26. Margin normalization is anticipated to take approximately one year post the Jun'26 capacity additions, with a step-up in operating expenses expected starting in Sep'26. [Status: Initiated]
4 more themes on the ELITE plan.